कृपया अन्य खोज का प्रयास करें
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
नाम | आयु | पहले | शीर्षक |
---|---|---|---|
Errol B. De Souza | 70 | 2021 | Independent Chairman |
Peter M. Hecht | 59 | 2019 | Director |
Mark G. Currie | 68 | 2019 | Chair of Scientific Advisory Board |
Terrance G. McGuire | 67 | 2019 | Independent Director |
Robert C. Malenka | - | 2021 | Member of Scientific Advisory Board |
Marni Joy Falk | - | 2021 | Member of Scientific Advisory Board |
David H. Salat | - | 2021 | Member of Clinical Advisory Board |
Daniela Salvemini | - | 2021 | Member of Scientific Advisory Board |
Andrew E. Budson | - | 2021 | Member of Clinical Advisory Board |
Claudio Babiloni | - | 2021 | Member of Scientific Advisory Board |
M Brandon Westover | - | 2021 | Member of Clinical Advisory Board |
Harald H. H. W. Schmidt | - | 2021 | Member of Scientific Advisory Board |
Steven E. Hyman | 72 | 2022 | Independent Director |
Eric Smith | - | 2021 | Member of Clinical Advisory Board |
Dina Katabi | - | 2023 | Director |
Michael J. Higgins | 62 | 2023 | Director |
क्या आप सच में %USER_NAME% को ब्लॉक करना चाहते हैं?
ऐसा करके, आप और %USER_NAME% नहीं देख पाएंगे किसी अन्य के Investing.com की पोस्ट में से कोई भी।
%USER_NAME% को सफलतापूर्वक आपकी ब्लॉक सूची में जोड़ लिया गया है
क्योंकि आपने इस व्यक्ति को अनब्लॉक कर दिया है, आपको ब्लॉक को रिन्यू करने से पहले 48 घंटे प्रतीक्षा करनी होगी।
मुझे लगता है कि यह टिपण्णी:
धन्यवाद!
आपकी रिपोर्ट समीक्षा के लिए हमारे मॉडरेटर को भेजी गई है